Twenty years ago, doctors treated cancer with three tools: surgery, radiation, and chemotherapy — all of which attack the tumor directly. Immunotherapy is a fundamentally different idea: teach the patient's own immune system to recognize and destroy cancer cells. It has already saved thousands of lives with cancers that were considered untreatable a decade ago.
What you'll read
How immunotherapy works
Your immune system is designed to find and kill abnormal cells. Cancer cells survive by hiding — they display molecular signals that tell your T-cells 'don't attack, I'm normal.' Immunotherapy either removes this camouflage or trains the immune system to recognize the tumor anyway.
The Nobel Prize in Medicine (2018) was awarded to James Allison and Tasuku Honjo for exactly this discovery — the checkpoint proteins PD-1 and CTLA-4 that tumors exploit.
The four main types of immunotherapy
1. Checkpoint inhibitors
The most widely used type. Drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) block the 'off switches' cancer uses on T-cells. Effective in melanoma, lung, kidney, bladder, head and neck, and many other cancers. Given as an IV infusion every 2–6 weeks.
2. CAR-T cell therapy
Chimeric Antigen Receptor T-cell therapy. Doctors remove your T-cells, genetically engineer them in a lab to display a receptor that locks onto your specific cancer, multiply them, and infuse them back. Approved for certain leukemias, lymphomas, and multiple myeloma. Complete remission in patients who had failed every other treatment.
3. Monoclonal antibodies
Lab-made antibodies designed to attach to specific proteins on cancer cells, either flagging them for destruction or blocking growth signals. Trastuzumab (Herceptin) for HER2+ breast cancer and rituximab (Rituxan) for non-Hodgkin lymphoma are classic examples.
4. Cancer vaccines
Different from a preventive vaccine like the HPV shot. Therapeutic cancer vaccines are given after diagnosis to boost the immune response against tumor antigens. Sipuleucel-T (Provenge) for advanced prostate cancer is the classic example; newer mRNA-based vaccines from Moderna and BioNTech are in late-stage trials for melanoma and pancreatic cancer.
Which cancers respond to immunotherapy
Response rates vary enormously by cancer type and by tumor biomarkers (PD-L1 expression, tumor mutational burden, microsatellite instability). Cancers with strong immunotherapy response include:
- Melanoma (metastatic): 40–50% durable response with combination checkpoint inhibitors
- Non-small cell lung cancer with high PD-L1: pembrolizumab first-line
- Kidney (renal cell) cancer: combination immunotherapy has replaced older targeted therapies as standard
- Bladder cancer, head and neck cancers, Hodgkin lymphoma, triple-negative breast cancer, certain colorectal cancers (MSI-high)
Some cancers — pancreatic, glioblastoma, most prostate cancers — remain largely resistant, though research is active.
Side effects to know
Immunotherapy generally has fewer traditional side effects than chemotherapy (less nausea, less hair loss), but it carries a distinct risk: the activated immune system can attack healthy tissues. These 'immune-related adverse events' can affect any organ:
- Skin: rash, itching
- Colon: diarrhea, colitis
- Lungs: pneumonitis
- Endocrine glands: thyroid, adrenal, or pituitary dysfunction
- Liver: hepatitis
Most are manageable if caught early. The critical thing is prompt communication with your oncology team about any new symptom.
Cost — the honest picture
Immunotherapy is expensive. In the U.S., a year of pembrolizumab costs about $180,000 at list price; CAR-T can exceed $1 million total. In Türkiye at JCI-accredited hospitals, the same drugs are typically 60–70% less. Most patients still need chemotherapy or radiation alongside — a full personalized quote is the only honest number.
What's next
Personalized cancer vaccines using mRNA technology, TIL therapy for solid tumors, bispecific antibodies, and combinations that overcome resistance — the field is moving faster than any other area of oncology.
Would immunotherapy work for your case?
Send your pathology report — a board-certified oncologist will tell you whether biomarker testing and immunotherapy are indicated.